UY32302A - Carboxamidas heterobicíclicas como inhibidoras de cinasas - Google Patents

Carboxamidas heterobicíclicas como inhibidoras de cinasas

Info

Publication number
UY32302A
UY32302A UY0001032302A UY32302A UY32302A UY 32302 A UY32302 A UY 32302A UY 0001032302 A UY0001032302 A UY 0001032302A UY 32302 A UY32302 A UY 32302A UY 32302 A UY32302 A UY 32302A
Authority
UY
Uruguay
Prior art keywords
carboxamids
heterobicyclic
diseases
formula
treatment
Prior art date
Application number
UY0001032302A
Other languages
English (en)
Inventor
Gerald David Artman Iii
Jason Matthew Elliott
Ji Nan
Liu Donglei
Ma Fupeng
Mainolfi Nello
Meredith Erik
Miranda Karl
James J Powers
Rao Chang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42034535&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY32302(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY32302A publication Critical patent/UY32302A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a compuestos orgánicos novedosos de la fórmula (I): y a su uso en el tratamiento del cuerpo animal o humano, a las composiciones farmacéuticas que comprenden un compuesto de la fórmula I, y al uso de un compuesto de la fórmula I para la preparación de composiciones farmacéutica para utilizarse en el tratamiento de enfermedades dependientes de la cinasa de proteína, en especial de enfermedades proliferativas, tal como en el tratamiento de enfermedades tumorales y enfermedades neovasculares oculares.
UY0001032302A 2008-12-09 2009-12-07 Carboxamidas heterobicíclicas como inhibidoras de cinasas UY32302A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20124308P 2008-12-09 2008-12-09
US23334109P 2009-08-12 2009-08-12

Publications (1)

Publication Number Publication Date
UY32302A true UY32302A (es) 2010-07-30

Family

ID=42034535

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032302A UY32302A (es) 2008-12-09 2009-12-07 Carboxamidas heterobicíclicas como inhibidoras de cinasas

Country Status (39)

Country Link
US (6) US8242125B2 (es)
EP (1) EP2376478B1 (es)
JP (1) JP5580330B2 (es)
KR (1) KR101345956B1 (es)
CN (2) CN102307870B (es)
AR (1) AR074499A1 (es)
AU (1) AU2009326110B9 (es)
BR (1) BRPI0922552A2 (es)
CA (1) CA2745922C (es)
CL (1) CL2011001378A1 (es)
CO (1) CO6382119A2 (es)
CR (1) CR20110270A (es)
CU (1) CU24097B1 (es)
CY (1) CY1119091T1 (es)
DK (1) DK2376478T3 (es)
EA (1) EA019681B1 (es)
EC (1) ECSP11011113A (es)
ES (1) ES2633959T3 (es)
HN (1) HN2011001593A (es)
HR (1) HRP20171075T1 (es)
HU (1) HUE035292T2 (es)
IL (1) IL213068A (es)
JO (1) JO3265B1 (es)
LT (1) LT2376478T (es)
MX (1) MX2011006093A (es)
MY (1) MY155649A (es)
NZ (2) NZ593030A (es)
PE (1) PE20110835A1 (es)
PL (1) PL2376478T3 (es)
PT (1) PT2376478T (es)
RS (1) RS56076B1 (es)
SG (1) SG171784A1 (es)
SI (1) SI2376478T1 (es)
SV (1) SV2011003939A (es)
TN (1) TN2011000263A1 (es)
TW (1) TWI429640B (es)
UY (1) UY32302A (es)
WO (1) WO2010066684A2 (es)
ZA (1) ZA201103759B (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2350075T3 (pl) 2008-09-22 2014-07-31 Array Biopharma Inc Podstawione związki imidazo[1,2b]pirydazynowe jako inhibitory kinaz Trk
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
ES2547145T3 (es) 2010-10-27 2015-10-02 Novartis Ag Regímenes de dosificación para el tratamiento de enfermedad vascular ocular
CN102786469B (zh) * 2011-05-18 2016-09-14 中国医学科学院药物研究所 邻吡啶酰肼衍生物及其制法和药物组合物与用途
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
CA2872000A1 (en) * 2012-05-04 2013-11-07 Novartis Ag Complement pathway modulators and uses thereof
KR101315227B1 (ko) * 2012-05-30 2013-10-07 엘지디스플레이 주식회사 터치스크린 일체형 표시장치 및 그 구동 방법
US9487483B2 (en) * 2012-06-28 2016-11-08 Novartis Ag Complement pathway modulators and uses thereof
EP2867229B1 (en) * 2012-06-28 2017-07-26 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
JP6273274B2 (ja) * 2012-06-28 2018-01-31 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
ES2647124T3 (es) * 2012-06-28 2017-12-19 Novartis Ag Derivados de pirrolidina y su uso como moduladores de la ruta del complemento
JP6209605B2 (ja) * 2012-06-28 2017-10-04 ノバルティス アーゲー ピロリジン誘導体、および補体経路調節因子としてのその使用
MX2014015738A (es) * 2012-06-28 2015-08-06 Novartis Ag Derivados de pirrolidina y su uso como moduladores de la senda del complemento.
EP2872503B1 (en) * 2012-07-12 2018-06-20 Novartis AG Complement pathway modulators and uses thereof
CN103570616B (zh) * 2012-07-18 2017-10-20 中国医学科学院药物研究所 N′‑直链烷酰基邻吡啶酰肼衍生物及其制法和药物组合物与用途
EP2970269B1 (en) 2013-03-14 2017-04-19 Novartis AG 2-(1h-indol-4-ylmethyl)-3h-imidazo[4,5-b]pyridine-6-carbonitrile derivatives as complement factor b inhibitors useful for the treatment of ophthalmic diseases
CN106146473B (zh) * 2013-03-28 2020-04-14 宁波市方昌医药有限公司 一种抗血管新生化合物
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
US10174006B2 (en) * 2013-06-06 2019-01-08 Novartis Ag Topical aqueous ophthalmic compositions containing a 1H-indole-1-carboxamide derivative and use thereof for treatment of ophthalmic disease
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
EP3028703B1 (en) 2013-07-29 2019-12-04 Kyowa Kirin Co., Ltd. Piperidine derivatives as wnt signaling inhibitor
JP2016535042A (ja) 2013-10-30 2016-11-10 ノバルティス アーゲー ２−ベンジル−ベンゾイミダゾール補体因子ｂ阻害剤およびその使用
US20160351119A1 (en) * 2014-02-06 2016-12-01 Joled Inc. Display apparatus
JP2017206437A (ja) * 2014-08-18 2017-11-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 ４−アミノピリジン誘導体
WO2016137506A1 (en) 2015-02-27 2016-09-01 Nantbioscience, Inc. Pyrimidine derivatives as kinase inhibitors and their therapeutical applications
EP3317258A4 (en) * 2015-07-01 2019-06-26 Pharmakea, Inc. LYSYL OXIDASE LIKE 2 INHIBITORS AND USES THEREOF
CA2992586A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
EP3368039A1 (en) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Point mutations in trk inhibitor-resistant cancer and methods relating to the same
MY197370A (en) 2015-11-06 2023-06-14 Hoffmann La Roche Indolin-2-one derivatives
JP6839184B2 (ja) 2015-11-06 2021-03-03 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ インドリン−２−オン誘導体
CN108137555B (zh) 2015-11-06 2021-02-19 豪夫迈·罗氏有限公司 可用于治疗cns疾病的二氢吲哚-2-酮衍生物
EP3371169B1 (en) 2015-11-06 2019-07-17 H. Hoffnabb-La Roche Ag Indolin-2-one derivatives for use in the treatment of cns and related disorders
GEP20227339B (en) 2016-04-04 2022-01-25 Loxo Oncology Inc Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)- pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydro-xypyrrolidine-1-carboxamide
EP3439663B1 (en) 2016-04-04 2024-07-17 Loxo Oncology, Inc. Methods of treating pediatric cancers
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
CA3024603A1 (en) 2016-05-18 2017-11-23 Charles Todd Eary Process for the preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
WO2018069893A1 (en) 2016-10-14 2018-04-19 Novartis Ag Methods for treating ocular disease using inhibitors of csf-1r
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
TW202410896A (zh) 2017-10-10 2024-03-16 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
TWI802635B (zh) 2018-01-18 2023-05-21 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物
CN108586454B (zh) * 2018-02-13 2021-02-26 沈阳药科大学 四氢吡啶并[4,3-d]嘧啶类衍生物及其用途
CN110386892B (zh) * 2018-04-16 2020-08-18 新发药业有限公司 一种4-氟-5-羟基-2-甲基-1h-吲哚的制备方法
CN110483482A (zh) * 2018-05-15 2019-11-22 北京诺诚健华医药科技有限公司 吲哚啉-1-甲酰胺类化合物、其制备方法及其在医药学上的应用
KR102653681B1 (ko) 2018-07-31 2024-04-03 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제
CA3111984A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
WO2020131674A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
KR20210151818A (ko) 2019-04-12 2021-12-14 내셔날 헬스 리서치 인스티튜트 치료 용도를 위한 키나제 억제제로서의 헤테로사이클릭 화합물
CA3161339A1 (en) 2019-12-27 2021-07-01 Schrodinger, Inc. Cyclic compounds and methods of using same
EP4186894A4 (en) * 2020-08-11 2024-01-17 Henan Medinno Pharmaceutical Technology Co., Ltd. FGFR INHIBITOR COMPOUND AND ITS USE
WO2022055963A1 (en) 2020-09-10 2022-03-17 Schrödinger, Inc. Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer
US20240148732A1 (en) 2021-01-26 2024-05-09 Schrödinger, Inc. Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders
TW202300150A (zh) 2021-03-18 2023-01-01 美商薛定諤公司 環狀化合物及其使用方法
AU2023209631A1 (en) 2022-01-24 2024-07-25 Novartis Ag Spirocyclic piperidinyl derivatives as complement factor b inhibitors and uses thereof
TW202346279A (zh) 2022-04-01 2023-12-01 瑞士商諾華公司 補體因子ｂ抑制劑及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE295365T1 (de) 2000-02-09 2005-05-15 Novartis Pharma Gmbh Pyridinderivative als angiogenese- und/oder vegf- rezeptor-tyrosinkinase-inhibitoren
KR100600550B1 (ko) * 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
GB0126902D0 (en) 2001-11-08 2002-01-02 Novartis Ag Organic compounds
AR037647A1 (es) * 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
CA2488739A1 (en) * 2002-08-30 2004-03-11 Eisai Co., Ltd. Nitrogen-containing aromatic derivatives
TW200418466A (en) * 2002-11-06 2004-10-01 Smithkline Beecham Corp Chemical compounds
SE0302324D0 (sv) 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
PE20060664A1 (es) * 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
GB0420520D0 (en) * 2004-09-15 2004-10-20 Novartis Ag Organic compounds
GB0421525D0 (en) * 2004-09-28 2004-10-27 Novartis Ag Inhibitors of protein kineses
DOP2006000051A (es) 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
GT200600411A (es) 2005-09-13 2007-05-21 Novartis Ag Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular
RU2481840C2 (ru) 2006-04-07 2013-05-20 Новартис Аг КОМБИНАЦИЯ, ВКЛЮЧАЮЩАЯ А) ПИРИМИДИЛАМИНОБЕНЗАМИД И Б) ИНГИБИТОР КИНАЗЫ Thr315lle
US20090176778A1 (en) 2007-08-10 2009-07-09 Franz Ulrich Schmitz Certain nitrogen containing bicyclic chemical entities for treating viral infections
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
TWI440638B (zh) 2007-10-30 2014-06-11 Otsuka Pharma Co Ltd 雜環化合物及其藥學組成物

Also Published As

Publication number Publication date
HUE035292T2 (en) 2018-05-02
DK2376478T3 (en) 2017-07-31
WO2010066684A3 (en) 2010-10-14
CN102307870B (zh) 2014-06-18
HRP20171075T1 (hr) 2017-10-06
IL213068A0 (en) 2011-07-31
MY155649A (en) 2015-11-13
CL2011001378A1 (es) 2011-11-25
CY1119091T1 (el) 2018-01-10
US8541432B2 (en) 2013-09-24
US8486954B2 (en) 2013-07-16
HN2011001593A (es) 2014-01-20
US20130012529A1 (en) 2013-01-10
US20100168082A1 (en) 2010-07-01
US20130005750A1 (en) 2013-01-03
US20120245187A1 (en) 2012-09-27
EA019681B1 (ru) 2014-05-30
CN102307870A (zh) 2012-01-04
CN103193773A (zh) 2013-07-10
ECSP11011113A (es) 2011-07-29
US20130005751A1 (en) 2013-01-03
JP5580330B2 (ja) 2014-08-27
AU2009326110A1 (en) 2011-06-23
AU2009326110B9 (en) 2013-10-31
TN2011000263A1 (en) 2012-12-17
CN103193773B (zh) 2014-12-10
TWI429640B (zh) 2014-03-11
RS56076B1 (sr) 2017-10-31
IL213068A (en) 2017-02-28
JP2012511535A (ja) 2012-05-24
US8492393B2 (en) 2013-07-23
AU2009326110B2 (en) 2013-09-12
TW201026686A (en) 2010-07-16
PL2376478T3 (pl) 2017-10-31
PE20110835A1 (es) 2011-11-25
PT2376478T (pt) 2017-06-30
MX2011006093A (es) 2011-06-21
US8501756B2 (en) 2013-08-06
EA201100873A1 (ru) 2011-12-30
WO2010066684A2 (en) 2010-06-17
CU24097B1 (es) 2015-06-30
US8431584B2 (en) 2013-04-30
ZA201103759B (en) 2012-01-25
JO3265B1 (ar) 2018-09-16
US8242125B2 (en) 2012-08-14
BRPI0922552A2 (pt) 2021-11-03
EP2376478A2 (en) 2011-10-19
ES2633959T3 (es) 2017-09-26
CU20110129A7 (es) 2012-01-31
NZ593030A (en) 2013-11-29
US20130005753A1 (en) 2013-01-03
SI2376478T1 (sl) 2017-07-31
NZ601656A (en) 2013-11-29
KR20110098799A (ko) 2011-09-01
AR074499A1 (es) 2011-01-19
CA2745922A1 (en) 2010-06-17
SV2011003939A (es) 2011-07-28
KR101345956B1 (ko) 2014-02-06
LT2376478T (lt) 2017-07-10
EP2376478B1 (en) 2017-04-19
CR20110270A (es) 2011-06-28
CA2745922C (en) 2017-06-27
SG171784A1 (en) 2011-07-28
CO6382119A2 (es) 2012-02-15

Similar Documents

Publication Publication Date Title
UY32302A (es) Carboxamidas heterobicíclicas como inhibidoras de cinasas
ECSP077324A (es) Amidas bicíclicas como inhibidores de cinasa
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
NI201000145A (es) DERIVADOS DE IMIDAZO - [1, 2-b] - PIRIDAZINA PARA EL TRATAMIENTO DE ENFERMEDAD MEDIADA POR CINASA DE TIROSINA C-MET.
CR11201A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
UY31952A (es) 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
CR11200A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o p13k
CU20100062A7 (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteínas quinasas b
ECSP109934A (es) Compuesto - 946
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
CO6690816A2 (es) Derivados de quinazolin-4(3h)-ona utilizados como inhibidores de pi3 cinasa
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
CL2011000504A1 (es) Compuestos derivados de piridin-4-il-tiazol-2il-amida 2-amida-pirrolidin-1,2-dicarboxilico, inhibidores de quinasa de fosfatidil-inositol-3; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de un medicamento para el tratamiento del cancer.
BRPI0915084B8 (pt) composto, e, composição farmacêutica
CL2011001967A1 (es) Compuestos derivados de carboxamida-azaheterociclica sustituida, inhibidores de p70s6k, proceso de preparacion de estos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y cancer; kit farmaceutico.
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
CL2009000445A1 (es) Compuestos derivados de piperidina 1,4 heterociclo sustituidos, procedimiento para preparar estos compuestos, composicion farmaceutica que los comprende y su uso para la terapia del dolor y el tratamiento de enfermedades como alzheimer, esquizofrenia, ansiedad y depresion.
UY32829A (es) Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo
CO6341625A2 (es) Derivados de indol como agentes anticáncer
UY29358A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento
CU20100175A7 (es) Derivados de imidazo-[1,2-b]-piridazina para el tratamiento de enfermedad mediada por cinasa de tirosina c-met
CU20100003A7 (es) Derivados trisustituídas de pirimidina para el tratamiento de enfermedades proliferativas
CU20080120A7 (es) Derivados de pirimidinil aril urea e inhibidores fgf

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210226